Wide Ranks

CGEN

Compugen Ltd.

1.61

Top Statistics
Market Cap 144 M Forward PE -5.96 Revenue Growth 0.00 %
Current Ratio 4.12 Trailing PE 53.67 Earnings Growth 0.00 %
Profit Margins -22.31 % Peg Ratio Dividend Yield 0.00 %
Enterprice / EBITA -13.33 Enterprise / Revenue 1.27 Price To Sales Trailing12 Months 3.37
Profitability
Profit Margins -22.31 % Operating Margins -50.91 %
Balance Sheet
Total Cash 92 M Total Cash Per Share 1.03 Total Debt 3 M
Total Debt To Equity 5.19 Current Ratio 4.12 Book Value Per Share 0.7350
All Measures
Short Ratio 642.00 % Message Board Id finmb_166115 Fax 972 3 765 8555
Shares Short Prior Month 1 M Return On Equity -0.1584 City Holon
Uuid 1985262d-ab80-3c43-a2e1-6782924ab738 Previous Close 1.52 First Trade Date Epoch Utc 966 M
Book Value 0.7350 Beta 2.65 Total Debt 3 M
Volume 1 M Price To Book 2.19 Fifty Two Week Low 0.6500
Total Cash Per Share 1.03 Total Revenue 42 M Shares Short Previous Month Date 1 B
Target Median Price 4.00 Max Age 86400 Sand P52 Week Change 0.3133
Operating Margins -50.91 % Target Mean Price 4.00 Net Income To Common -9529000
Short Percent Of Float 0.0147 Implied Shares Outstanding 89 M Trailing Peg Ratio None
Last Fiscal Year End 1 B Average Daily Volume10 Day 394980 Average Volume10days 394980
Total Cash 92 M Next Fiscal Year End 1 B Revenue Per Share 0.4800
Held Percent Insiders 0.0538 Ebitda Margins -9.53 % Trailing PE 53.67
Date Short Interest 1 B Most Recent Quarter 1 B Regular Market Previous Close 1.52
Target Low Price 4.00 Gmt Off Set Milliseconds -18000000 Fifty Day Average 1.68
Open 1.56 Free Cashflow 8 M Dividend Yield 0.00 %
Return On Assets -0.0304 Time Zone Short Name EST Trailing Eps 0.0300
Day Low 1.53 Address1 Azrieli Center Shares Outstanding 89 M
Price Hint 4 Target High Price 4.00 Website https://cgen.com
52 Week Change 1.44 Average Volume 255629 Forward Eps -0.1100
Recommendation Key none Compensation As Of Epoch Date 1 B Quick Ratio 411.00 %
Is_sp_500 False Regular Market Day High 1.67 Profit Margins -22.31 %
Debt To Equity 5.19 Fifty Two Week High 3.03 Day High 1.67
Shares Short 1 M Regular Market Open 1.56 Industry Key biotechnology
Earnings Growth 0.00 % Enterprise To Revenue 1.27 Revenue Growth 0.00 %
Shares Percent Shares Out 0.0142 Operating Cashflow 22 M Currency USD
Time Zone Full Name America/New_York Market Cap 144 M Is_nasdaq_100 False
Zip 5885849 Quote Type EQUITY Industry Biotechnology
Long Name Compugen Ltd. Regular Market Day Low 1.53 Held Percent Institutions 0.1497
Current Price 1.61 Address2 Building D 26 Harokmim Street Enterprise To Ebitda -13.33
Financial Currency USD Current Ratio 4.12 Gross Margins 86.76 %
Industry Disp Biotechnology Number Of Analyst Opinions 2 Country Israel
Float Shares 84 M Two Hundred Day Average 1.99 Ir Website http://cgen.com/investors
Enterprise Value 54 M Price To Sales Trailing12 Months 3.37 Forward PE -5.96
Regular Market Volume 1 M Ebitda -4071000 Exchange NCM
Go to Yahoo Finance Go to Seeking Alpha 
Compugen Ltd.

, a clinical-stage therapeutic discovery and development company, researches, develops, and commercializes therapeutic and product candidates in Israel, the United States, and Europe.

The company's immuno-oncology pipeline consists of COM701, an anti-PVRIG antibody that is in Phase I clinical study used for the treatment of solid tumors; COM902, a therapeutic antibody targeting TIGIT, which is in Phase I monotherapy clinical study in patients with advanced malignancies through sequential dose escalations; Bapotulimab, a therapeutic antibody targeting ILDR2 that is in Phase I clinical study in patients with naïve head and neck squamous cell carcinoma; and Rilvegostomig, a novel anti-TIGIT/PD-1 bispecific antibody, which is in Phase II clinical study in patients with advanced or metastatic non-small cell lung cancer.

Its therapeutic pipeline also includes early-stage immuno-oncology programs focused to address various mechanisms of immune resistance; and COM503, high affinity antibody, which blocks the interaction between IL-18 binding protein and IL-18.

The company has collaboration agreement with Bayer Pharma AG for the research, development, and commercialization of antibody-based therapeutics against the company's immune checkpoint regulators; Bristol-Myers Squibb to evaluate the safety and tolerability of COM701 in combination with Bristol-Myers Squibb's PD-1 immune checkpoint inhibitor Opdivo in patients with advanced solid tumors; and Johns Hopkins School of Medicine to evaluate novel T cell and myeloid checkpoint targets.

It has license agreement with AstraZeneca for the development of bi-specific and multi-specific immuno-oncology antibody products; and research collaboration with Johns Hopkins University for myeloid.

Compugen Ltd.

was incorporated in 1993 and is headquartered in Holon, Israel.